CN Patent

CN110563733A — 作为选择性btk抑制剂的咪唑并吡嗪类化合物

Assigned to An Dikang (wuxi) Biotechnology Co Ltd · Expires 2019-12-13 · 6y expired

What this patent protects

本发明涉及作为选择性布鲁顿酪氨酸激酶(BTK)抑制剂的咪唑并吡嗪类化合物。具体而言，本发明公开了(S)‑4‑(8‑氨基‑3‑(1‑(丁‑2‑炔酰基)吡咯烷‑2‑基)咪唑并[1,5‑a]吡嗪‑1‑基)‑N‑(吡啶‑2‑基)苯甲酰胺和其光学异构体的氘代化合物，或药学上可接受的盐或涉及含有这类化合物的药物组合物，以及他们在治疗BTK介导的疾病中的用途。

USPTO Abstract

本发明涉及作为选择性布鲁顿酪氨酸激酶(BTK)抑制剂的咪唑并吡嗪类化合物。具体而言，本发明公开了(S)‑4‑(8‑氨基‑3‑(1‑(丁‑2‑炔酰基)吡咯烷‑2‑基)咪唑并[1,5‑a]吡嗪‑1‑基)‑N‑(吡啶‑2‑基)苯甲酰胺和其光学异构体的氘代化合物，或药学上可接受的盐或涉及含有这类化合物的药物组合物，以及他们在治疗BTK介导的疾病中的用途。

Drugs covered by this patent

Patent Metadata

Patent number
CN110563733A
Jurisdiction
CN
Classification
—
Expires
2019-12-13
Drug substance claim
No
Drug product claim
No
Assignee
An Dikang (wuxi) Biotechnology Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.